share_log

Mikra Commences Commercial Scale Production of Upgraded CELLF

Mikra Commences Commercial Scale Production of Upgraded CELLF

米克拉開始商業規模生產升級後的 CELF
GlobeNewswire ·  2023/01/30 07:08

Marks major milestone toward imminent availability for sale to customers

標誌着即將向客户銷售的重要里程碑

TORONTO, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. ("Lifeist" or the "Company") (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS: NXTTF), a health-tech company that leverages advancements in science and technology to build breakthrough companies that transform human wellness, today announced that its U.S. biosciences subsidiary Mikra Cellular Sciences Inc. ("Mikra") has begun commercial scale production of a new and improved version of CELLF.

多倫多,2023年1月30日(環球通訊社)--Lifeist Wellness Inc.(“Lifeist”或“公司”)(多倫多證券交易所股票代碼:LFST)(法蘭克福股票代碼:M5B)(OTCMKTS:NXTTF)一家利用科技進步打造能夠改變人類健康的突破性公司的健康科技公司今天宣佈,其美國生物科學子公司Mikra細胞科學公司(“Mikra”)已開始商業規模生產一種新的改良版本的CELLF。

"Starting production of this new and improved version of CELLF is a major milestone following a lot of hard work behind the scenes by Mikra's team both on R&D and sourcing of new packaging and materials," said Meni Morim, CEO of Lifeist. "This advancement brings Mikra one step closer to shipping the new version to customers, and will help Mikra deliver on the promise of becoming a more meaningful contributor to Lifeist's financial performance in 2023."

Lifeist首席執行官梅尼·莫里姆表示:“在Mikra的團隊在研發和採購新包裝和材料方面進行了大量幕後艱苦工作後,開始生產這個新的改進版本是一個重要的里程碑。”這一進展使Mikra距離向客户交付新版本又近了一步,並將幫助Mikra兑現承諾,成為Lifeist 2023年財務業績的更有意義的貢獻者。

Added Faraaz Jamal, CEO of Mikra and COO of Lifeist, "When we first created CELLF, we prioritized efficacy, potency and safety, with the goal of establishing Mikra as an innovator in the market. This meant we made cognizant sacrifices with the first version of the formula in order to assure that we were making a safe product that really worked and lived up to our standards. With a successful launch under our belts, and a loyal consumer base, we are now positioned to build on the prior innovations while making improvements based on heartfelt customer feedback. The result of this R&D journey is beyond our expectations, and we look forward to introducing these upgrades to established and new customers."

Mikra首席執行官兼Lifeist首席運營官Faraaz Jamal補充道:“當我們第一次創建CELLF時,我們將療效、效力和安全性放在首位,目標是將Mikra打造成市場上的創新者。這意味着我們在配方的第一個版本上做出了公認的犧牲,以確保我們製造的是真正有效並符合我們標準的安全產品。隨着我們的成功推出,以及忠誠的消費者基礎,我們現在已經準備好在之前的創新基礎上再接再厲,同時根據客户真誠的反饋進行改進。這次研發之旅的結果超出了我們的預期,我們期待着將這些升級介紹給現有客户和新客户。

The key improvements in the upgraded version of CELLF include:

CELLF升級版的主要改進包括:

  • Significantly better taste
  • Brand new, one-handed accessible sachet design
  • Protective, environmentally friendly exterior packaging
  • Now dairy-free & vegan with no impact to delivery technology
  • 口感明顯更好
  • 全新的單手無障礙香包設計
  • 環保型外包裝
  • 現在不含乳製品和素食,對送貨技術沒有影響

"The new version of CELLF effectively addresses the feedback we received with version one, removing most major barriers in the sales funnel to purchase and increasing the probability of both customer retention and winback as we continue to grow and nurture our repeat customer community," said Jamal. "As we have recently seen, this incremental improvement has already opened up more distribution opportunities and we believe it will lead to higher gross margins and higher customer lifetime value."

賈馬爾説:“新版本的CELLF有效地解決了我們在第一版中收到的反饋,消除了購買銷售漏斗中的大多數主要障礙,並隨着我們繼續發展和培育我們的回頭客羣體,增加了留住客户和贏回客户的可能性。”正如我們最近看到的那樣,這種漸進的改進已經打開了更多的分銷機會,我們相信這將帶來更高的毛利率和更高的客户終身價值。“

Concluded Jamal, "The evolution of CELLF was a necessary step to solidify it as Mikra's flagship product and set the internal mindset that the key to business longevity is the absence of complacence. This is only the first of many strategic, iterative improvements we will make to our product suite to ensure our delivery meets or exceeds customer expectations."

賈馬爾總結道:“CELLF的發展是鞏固其作為Mikra旗艦產品的必要步驟,並確立了企業長盛不衰的關鍵是不自滿的內部思維。這只是我們將對我們的產品套件進行許多戰略性迭代改進的第一步,以確保我們的交付達到或超過客户的預期。”

When production is complete, the new and improved formula will be available for purchase at wearemikra.com and will be the debut version of the product sold at GNC stores and .

當生產完成後,新的和改進的配方將在wearemikra.com上購買,並將成為在GNC商店和銷售的產品的首個版本。

About Lifeist Wellness Inc.

關於Lifeist Wellness Inc.

Sitting at the forefront of the post-pandemic wellness revolution, Lifeist leverages advancements in science and technology to build breakthrough companies that transform human wellness. Portfolio business units include: CannMart, which operates a B2B wholesale distribution business facilitating recreational cannabis sales to Canadian provincial government control boards including for CannMart Labs, a BHO extraction facility producing high margin cannabis 2.0 products; Australian Vapes, one of Australia's largest online retailers of vaporizers and accessories; and Mikra, a biosciences and consumer wellness company developing and selling innovative therapies for cellular health.

坐在大流行後健康革命的前沿,Lifeist利用科學和技術的進步,建立了改變人類健康的突破性公司。業務組合包括:CannMart,經營B2B批發分銷業務,為向加拿大省級政府控制委員會銷售娛樂大麻提供便利,包括為CannMart Labs,一家生產高利潤率大麻2.0產品的BHO提取工廠;Australian Vapes,澳大利亞最大的蒸發器及配件在線零售商之一;以及Mikra,一家生物科學和消費者健康公司,開發和銷售針對細胞健康的創新療法。

Information on Lifeist and its businesses can be accessed through the links below:

有關Lifeist及其業務的信息可通過以下鏈接訪問:

lifeist.comcannmart.comroilty.coaustralianvaporizers.com.auwearemikra.com

Lifeist.comcannmart.comroilty.coaustralianvaporizers.com.auwearemikra.com

Contacts

聯繫人

Meni Morim, Lifeist Wellness Inc., CEO
Matt Chesler, CFA, FNK IR, Investor Relations
Ph: 647-362-0390
Email: ir@lifeist.com

Meni Morim,Lifeist Wellness Inc.首席執行官
馬特·切斯勒,CFA,FNK IR,投資者關係
電話:647-362-0390
電子郵件:ir@life ist.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release or has in any way approved or disapproved of the contents of this press release.

多倫多證券交易所及其監管服務提供商(該術語在多倫多證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任,也不以任何方式批准或不批准本新聞稿的內容。

Forward Looking Information

前瞻性信息

This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements contained herein that are not historical in nature contain forward-looking information. Forward-looking information can be identified by words or phrases such as "may", "expect", "likely", "should", "would", "plan", "anticipate", "intend", "potential", "proposed", "estimate", "believe" or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions "may" or "will" happen.

本新聞稿包含適用證券法所指的“前瞻性信息”。本文中包含的所有非歷史性陳述均含有前瞻性信息。前瞻性信息可以通過“可能”、“預期”、“可能”、“應該”、“將”、“計劃”、“預期”、“打算”、“潛在”、“建議”、“估計”、“相信”或這些術語的否定或其他類似的詞語、表達及其語法變體,或某些事件或條件“可能”或“將”發生的陳述來識別。

The forward-looking information contained herein, including, without limitation, statements related to the anticipated shipping to customers of the improved version of CELLF and the anticipated contribution to Lifeist's financial performance resulting from such sales during 2023, are made as of the date of this news release and is based on assumptions management believed to be reasonable at the time such statements were made, including, without limitation, expectations that and the improved version of CELLF will be available for purchase as anticipated and in a timely manner and gain market acceptance along with the expansion of the nutraceutical, its expectation that the market for nutraceutical products will remain strong and will continue to grow as currently anticipated, the nutraceutical market will continue to be a multi-billion dollar high-margin market, the introduction of new products, brands and distribution channels will generate additional awareness of Mikra's existing and future products and increase revenue. While we consider these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct. By its nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this press release. Such factors include, without limitation: unanticipated production issues or delays with respect to the improved version of CELLF; the failure to make the improved version of CELLF available for distribution and sale as anticipated in 2023, the Company's inability to continue to develop Mikra's business as a whole, including its inability to increase distribution through retail and online channels, unanticipated changes to current regulations that would adversely impact Mikra's business, unforeseen developments that would delay Mikra's ability to develop and sell any nutraceutical products, the risk that the expected demand for nutraceutical products in general and those of Mikra in particular, including consumer uptake, does not develop as anticipated and risks relating to the Company's ability to execute its business strategy and the benefits realizable therefrom. Additional risk factors can also be found in the Company's current MD&A which has been filed under the Company's SEDAR profile at . Readers are cautioned not to put undue reliance on forward-looking information. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

本文包含的前瞻性信息,包括但不限於與CELLF改進版的預期發貨和2023年期間此類銷售對Lifeist財務業績的預期貢獻有關的陳述,是截至本新聞稿發佈之日作出的,基於做出此類陳述時被認為合理的管理假設,包括但不限於對CELLF和改進版CELLF將按預期和及時提供購買並隨着營養食品的擴大而獲得市場接受的預期。該公司預計,保健品市場將保持強勁,並將像目前預期的那樣繼續增長,保健品市場將繼續是一個數十億美元的高利潤率市場,新產品、品牌和分銷渠道的推出將增加對Mikra現有和未來產品的認識,並增加收入。雖然根據管理層目前掌握的信息,我們認為這些假設是合理的,但不能保證這樣的預期將被證明是正確的。就其性質而言,前瞻性信息具有內在的風險和不確定性,這些風險和不確定性可能是一般性的,也可能是具體的,導致預期、預測或結論可能被證明不準確,假設可能不正確,目標、戰略目標和優先事項將無法實現。各種因素,包括已知和未知的風險,其中許多是我們無法控制的,可能會導致實際結果與本新聞稿中的前瞻性信息大不相同。這些因素包括, 但不限於:與CELLF改進版本有關的意外生產問題或延誤;未能按照預期在2023年提供CELLF的改進版本用於分銷和銷售,公司無法繼續發展Mikra的整體業務,包括它無法通過零售和在線渠道增加分銷,當前法規的意外變化將對Mikra的業務產生不利影響,意外的事態發展將推遲Mikra開發和銷售任何保健產品的能力,對一般保健產品,特別是Mikra的預期需求,包括消費者的吸收,未按預期發展,以及與公司執行其業務戰略的能力和由此可實現的利益相關的風險。其他風險因素也可以在公司目前的MD&A中找到,該報告已在公司的SEDAR簡介中提交,網址為。告誡讀者不要過度依賴前瞻性信息。除非適用法律要求,否則公司不承擔因新信息、未來事件或其他原因而更新或修改任何前瞻性信息的義務。本新聞稿中包含的前瞻性陳述明確地受到本警示性聲明的限制。

Source: Lifeist Wellness Inc.

來源:Lifeist Wellness Inc.


声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論